Medscape March 10, 2025
March 7, 2025 — The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only implantable therapy that uses cell technology to deliver a protein that helps slow the disease’s progression.
MacTel is a slowly progressing eye disease that damages the macula, the part of the eye responsible for sharp central vision needed for everyday tasks like reading, writing, driving, and recognizing faces. Over time, the light-sensing cells in both eyes break down, and the blood vessels supplying the macula become swollen and enlarged, leading to gradual vision loss.
Branded as Encelto, revakinagene taroretcel is a tiny implant containing lab-grown retinal cells....
Today's Sponsors
Today's Sponsor